Soft tissue tumors: Alveolar soft part sarcoma
نویسندگان
چکیده
منابع مشابه
Cytology of alveolar soft part sarcoma.
pherson in 1952 3). Its histogenesis is still uncertain, and there are few cytological articles about this tumor15). We tried cytological analysis of touch preparation of a case of alveolar soft part sarcoma and report on its cytological features. On the other hand, metastatic renal adenocarcinoma is necessary to be differentiated from alveolar soft part sarcoma, so we also performed imprint pr...
متن کاملAlveolar soft-part sarcoma of the retroperitoneum.
A 33-year-old woman was referred to Iida Municipal Hospital because of left back pain. Computed tomography showed a tumor (17 x 11 x 10 cm) in the left retroperitoneal space. T1- and T2-weighted magnetic resonance imaging showed an inhomogeneous mass with marginal blood vessels. The tumor was resected via lumbar oblique incision with the thoraco-abdominal approach. The tumor weighed 1800 g and ...
متن کاملAlveolar soft part sarcoma of flexure tendon
Alveolar soft part sarcoma (ASPS) is a very rare sarcoma, report <1% of all soft tissue tumor. Majority of cases were young adult and tumor occurred in lower extremities and trunk. Here, we present a case of 53-year-old Thai female with rapidly glowing mass over her right forearm. The magnetic resonance imaging scan demonstrated a hypervascular mass with multiple feeding vessels located in flex...
متن کاملAlveolar soft part sarcoma of the tongue.
Alveolar soft part sarcoma is a rare type of sarcoma that usually affects young adult women. It occurs mostly in the lower extremities, and nearly one quarter of the cases are found in the head and neck region. The most common site of origin in the head and neck region is the tongue followed by the orbit. Herein, we present an unusual case of alveolar soft part sarcoma of the tongue in an 18-ye...
متن کاملCediranib for metastatic alveolar soft part sarcoma.
PURPOSE Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor, for which no effective standard systemic treatment exists for patients with unresectable disease. Cediranib is a potent, oral small-molecule inhibitor of all three vascular endothelial growth factor receptors (VEGFRs). PATIENTS AND METHODS We conducted a phase II trial of once-daily cediranib (30 mg) given in 28-day c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Atlas of Genetics and Cytogenetics in Oncology and Haematology
سال: 2011
ISSN: 1768-3262
DOI: 10.4267/2042/38534